Trial
NCT02844582
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, Davis
Collaborators
Sanofi
Condition
Hormone-Resistant Prostate Cancer
Intervention
Cabazitaxel
Why stopped
Poor accrual of subjects onto study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-25